Trial Profile
PHASE II STUDY EVALUATION OF EFFICACITY AND TOLERANCE OF REGORAFENIB FOR 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL ADENOCARCINOMA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms REGOLD
- 13 Feb 2019 Status changed from recruiting to completed.
- 22 Sep 2015 New trial record